<unk>  is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
Capmatinib
Tucatinib
Neratinib
Fostamatinib
Dasatinib
Ponatinib
Lapatinib
Pemigatinib